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ABSTRACT 
Oral drug delivery system is the most preferred route of administration for drug delivery. In the development of the drug delivery 
system many components play important role. Polymers are amongst those components which have evolved with the drug delivery 
system. Polymers are the macromolecule compound containing many monomer units joined to each other by bonds. The floating 
drug delivery systems (FDDS) become an additional advantage for drugs that are absorbed primarily in the upper segments of 
gastrointestinal (GI) tract, i.e., the stomach, duodenum and jejunum. The purpose of writing this review on floating drug delivery 
systems (FDDS) was to focus on the types of floating drug delivery systems, principal and mechanism of floatation to achieve 
gastric retention and polymers used in floating Drug delivery systems. Polymers used in the drug delivery system are of two types 
Natural and Synthetic based on their origin. Both types of the polymers have some advantages and disadvantages. This particular 
article gives information about the different types of natural and synthetic polymer used in the drug delivery system. Natural 
polymers like guar gum, chitosan, xanthan gum, Gellan gum and sodium alginate are mentioned in the article. Synthetic polymers 
mentioned are HPMC, Eudragit, and Ethylcellulose. 
Keywords: Floating Drug Delivery System, Polymers, Natural gums, HPMC. 
 
Article Info: Received 21 Aug, 2018;   Review Completed 24 Sep 2018;   Accepted 25 Sep 2018;   Available online 15 Oct 2018 
Cite this article as: 
Zubedi SS, Mohammed S, Floating tablets and its polymers, Journal of Drug Delivery and Therapeutics. 2018; 
8(5-s):16-24      DOI: http://dx.doi.org/10.22270/jddt.v8i5-s.1928   
*Address for Correspondence:  
Shahid Mohammed, Department of Pharmaceutics, Deccan School of Pharmacy, Hyderabad-500001 
 
 
I.INTRODUCTION 
Oral administration is the most convenient and preferred 
means of any drug delivery to the systematic circulation. 
Oral controlled release drug delivery have recently been 
of increasing interest in pharmaceutical field to achieve 
improved therapeutic advantages, such as ease of dosing 
administration, patient compliance and flexibility in 
formulation. Drugs that are easily absorbed from 
gastrointestinal tract (GIT) and have short half-lives are 
eliminated quickly from the systemic circulation. 
Frequent dosing of these drugs is required to achieve 
suitable therapeutic activity. To avoid this limitation, the 
development of oral sustained-controlled release 
formulations is an attempt to release the drug slowly into 
the gastrointestinal tract (GIT) and maintain an effective 
drug concentration in the systemic circulation for a long 
time. After oral administration, such a drug delivery 
would be retained in the stomach and release the drug in 
a controlled manner, so that the drug could be supplied 
continuously to its absorption sites in the gastrointestinal 
tract (GIT) 
1
.
 
To formulate a site-specific orally 
administered controlled release dosage form, it is 
desirable to achieve a prolong gastric residence time by 
the drug delivery. Prolonged gastric retention improves 
bioavailability, increases the duration of drug release, 
reduces drug waste, and improves the drug solubility 
that are less soluble in a high pH environment 
2
. Also 
prolonged gastric retention time (GRT) in the stomach 
could be advantageous for local action in the upper part 
of the small intestine e.g. treatment of peptic ulcer, etc. 
Gastroretentive drug delivery is an approach to prolong 
gastric residence time, thereby targeting site-specific 
drug release in the upper gastrointestinal tract (GIT) for 
local or systemic effects. This elongated retention ability 
provides more benefits which may be enumerated as: 
improving activity span for short half-life drugs, 
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bioavailability of drugs, exclusion of side effects, 
reduction in dosage periodicity, saving drugs owing to 
former benefit, improves solubility for drugs that are less 
soluble in a high pH environment, optimized therapy and 
ultimately easy compliance on the part of the patient 
3, 4
. 
Over the last few decades, several gastroretentive drug 
delivery approaches being designed and developed, 
including: high density (sinking) systems that is retained 
in the bottom of the stomach 
5
, low density (floating) 
systems that causes buoyancy in gastric fluid 
6, 7, 8
, 
mucoadhesive systems that causes bioadhesion to 
stomach mucosa 
9
, unfoldable, extendible, or swellable 
systems which limits emptying of the dosage forms 
through the pyloric sphincter of stomach 
10, 11
, super 
porous hydrogel systems, magnetic systems etc. 
It is widely acknowledged that the extent of 
gastrointestinal tract drug absorption is related to contact 
time with the small intestinal mucosa 
12, 13
. Thus small 
intestinal transit time is an important parameter for drugs 
that are incompletely absorbed. 
1.1 FLOATING DRUG DELIVERY SYSTEM 
Floating drug delivery system is also known as 
hydrodynamically balanced system (HBS). While the 
system is floating on the gastric contents, the drug is 
released slowly at the desired rate from the system. After 
release of the drug, the residual system is emptied from 
the stomach. This results in an increased GRT and a 
better control of the fluctuations in plasma drug 
concentration
 14
. 
1.2 APPLICATIONS OF FLOATING DRUG 
DELIVERY SYSTEM 
Floating drug delivery offers several applications for 
drugs having poor bioavailability because of the narrow 
absorption window in the upper part of the 
gastrointestinal tract. It retains the dosage form at the 
site of absorption and thus enhances the bioavailability. 
These are summarized as follows. 
1. Sustained Drug Delivery  
HBS systems can remain in the stomach for long periods 
and hence can release the drug over a prolonged period 
of time. The problem of short gastric residence time 
encountered with an oral CR formulation hence can be 
overcome with these systems. These systems have a bulk 
density of <1 as a result of which they can float on the 
gastric contents. These systems are relatively large in 
size and passing from the pyloric opening is prohibited. 
Recently sustained release floating capsules of 
nicardipine hydrochloride were developed and were 
evaluated in vivo. The formulation compared with 
commercially available MICARD capsules using 
rabbits. Plasma concentration time curves showed a 
longer duration for administration (16 hours) in the 
sustained release floating capsules as compared with 
conventional MICARD capsules (8 hours) 
15
.  
Similarly a comparative study 
16
 between the Madopar 
HBS and Madopar standard formulation was done and it 
was shown that the drug was released up to 8 hours in 
vitro in the former case and the release was essentially 
complete in less than 30 minutes in the latter case.  
2. Site-Specific Drug Delivery  
These systems are particularly advantageous for drugs 
that are specifically absorbed from stomach or the 
proximal part of the small intestine, eg, riboflavin and 
furosemide. Furosemide is primarily absorbed from the 
stomach followed by the duodenum. It has been reported 
that a monolithic floating dosage form with prolonged 
gastric residence time was developed and the 
bioavailability was increased. AUC obtained with the 
floating tablets was approximately 1.8 times those of 
conventional furosemide tablets 
17
.  
A bilayer-floating capsule was developed for local 
delivery of misoprostol, which is a synthetic analog of 
prostaglandin E1 used as a protectant of gastric ulcers 
caused by administration of NSAIDs. By targeting slow 
delivery of misoprostol to the stomach, desired 
therapeutic levels could be achieved and drug waste 
could be reduced 
18
.  
3. Absorption Enhancement  
Drugs that have poor bioavailability because of site 
specific absorption from the upper part of the 
gastrointestinal tract are potential candidates to be 
formulated as floating drug delivery systems, thereby 
maximizing their absorption. A significant increase in 
the bioavailability of floating dosage forms (42.9%) 
could be achieved as compared with commercially 
available LASIX tablets (33.4%) and enteric coated 
LASIX-long product (29.5%) 
17
. 
 
Table 1: Commercially available floating Formulations
 37 
Name of the product Active Ingredient Category Name of Company 
Madopar HBS 
Capsule 
Levodopa (100mg) 
and Benserazide (25 mg) 
Anti-parkinsonial 
 
Roche, USA 
Valrelease Capsule Diazepam (15 mg) Anti-anxiety Hoffmann-La Roche, USA 
Liquid Gaviscon 
 
Al hydroxide (95 mg). 
Mg carbonate (358 mg) 
Antacid (in reflux 
esophagitis) 
Glaxo Smithkline, India 
 
Cytotec Bilayer capsule Misoprostol (100 mcg/200 mcg) - Pharmacia, USA 
Topalkan 
Alginic acid, Aluminium and 
Magnesium salts 
Antacid Pierre Fabre Drug, Frabce 
Almagate flowcoat Al-Mg antacid Antacid Ranbaxy, India 
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1.3 CLASSIFICATION OF FLOATING DRUG 
DELIVERY SYSTEM 
1. Single Unit Floating Dosage Systems  
a) Effervescent Systems (Gas-generating Systems) 
b) Non-effervescent Systems 
2. Multiple Unit Floating Dosage Systems  
a) Non-effervescent Systems  
b) Effervescent Systems (Gas-generating Systems)  
c) Hollow Microspheres 
d) Raft Forming Systems. 
1. Single Unit Floating Dosage Systems 
a) Effervescent Systems (Gas-generating Systems):  
These buoyant systems utilized matrices that are 
prepared with swellable polymers like HPMC, 
polysaccharides like chitosan, effervescent components 
such as sodium bicarbonate, citric acid and tartaric acid 
or chambers containing a liquid that gasifies at body 
temperature. The optimal stoichiometric ratio of citric 
acid and sodium bicarbonate for gas generation is 
reported to be 0.76:1. The common approach for 
preparing these systems involves resin beads loaded with 
bicarbonate and coated with ethylcellulose. The coating, 
which is insoluble but permeable, allows permeation of 
water. Thus, carbon dioxide is released, causing the 
beads to float in the stomach (Fig: 4). Excipients used 
most commonly in these systems include HPMC, 
polyacrylate polymers, polyvinyl acetate, Carbopol®, 
agar, sodium alginate, calcium chloride, polyethylene 
oxide and polycarbonates
 19
. 
b) Non-Effervescent Systems:  
This type of system, after swallowing, swells 
unrestrained via imbibitions of gastric fluid to an extent 
that it prevents their exit from the stomach. These 
systems may be referred as “plug-type systems‟ since 
they have a tendency to remain lodged near the pyloric 
sphincter. One of the formulation methods of such 
dosage forms involves the mixing of drug with a gel, 
which in contact with gastric fluid swells. The air 
trapped by the swollen polymer confers buoyancy to 
these dosage forms. Examples of this type of FDDS 
include colloidal gel barrier, micro porous compartment 
system, alginate beads, and hollow microspheres.  
Another type is a Fluid filled floating chamber which 
includes incorporation of a gas-filled floatation chamber 
into a micro porous component that houses a drug 
reservoir. Apertures or openings are present at the top 
and bottom walls through which the gastrointestinal tract 
fluid enters to dissolve the drug. The other two walls in 
contact with the fluid are sealed so that the undissolved 
drug remains therein. The fluid present could be air, 
under partial vacuum or any other suitable gas, liquid, or 
solid having an appropriate specific gravity and an inert 
behaviour. The device is of swellable size, remains 
afloat within the stomach for a prolonged period of time 
and after the complete release the shell disintegrates, 
passes off to the intestine, and is eliminated.  
A newer self-correcting floatable asymmetric 
configuration drug delivery system has a 3- layer matrix 
to control the drug release. This 3-layer principle has 
been improved by development of an asymmetric 
configuration drug delivery system in order to modulate 
the release extent and achieve zero-order release kinetics 
by initially maintaining a constant area at the diffusing 
front with subsequent dissolution/erosion toward the 
completion of the release process. The system was 
designed in such a manner that it floated to prolong 
gastric residence time in vivo, resulting in longer total 
transit time within the gastrointestinal tract environment 
with maximum absorptive capacity and consequently 
greater bioavailability.  
This particular characteristic would be applicable to 
drugs that have pH-dependent solubility, a narrow 
window of absorption, and are absorbed by active 
transport from either the proximal or distal portion of the 
small intestine
 19, 20
. 
2. Multiple Unit Floating Systems:  
In spite of extensive research and development in hydro 
dynamically balanced systems and other floating tablets, 
these systems has an important drawback of high 
variability of gastrointestinal transit time, when orally 
administered, because of their all-or nothing gastric 
emptying nature. In order to overcome this problem, 
multiple unit floating systems were developed, which 
reduces the inter-subject variability in absorption and 
lowers the probability of dose- dumping (Fig: 1).  
Reports have been found on the development of both 
non-effervescent and effervescent multiple unit systems. 
Much research has been focused and the scientists are 
still exploring the field of hollow microspheres, capable 
of floating on the gastric fluid and having improved 
gastric retention properties
 21
. 
 
Figure 1: Multiple unit of oral FDDS 
a) Non-effervescent Systems:  
Not much report was found in the literature on non-
effervescent multiple unit systems, as compared to the 
effervescent systems. However, few workers have 
reported the possibility of developing such system 
containing indomethacin, using chitosan as the 
polymeric excipient. A multiple unit HBS containing 
indomethacin as a model drug prepared by the extrusion 
process is reported. A mixture of drug, chitosan and 
acetic acid is extruded through a needle, and the 
extrudate is cut and dried. Chitosan hydrates and floats 
in the acidic media, & the required drug release could be 
obtained by modifying the drug-polymer ratio 
22
. 
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b) Effervescent Systems (Gas-generating Systems):  
There are reports of sustained release floating granules 
containing Tetracycline Hcl. The granules are a mixture 
of drug granulates of two stages i.e. A and B, of which A 
contains 60 parts of HPMC, 40 parts of polyacrylic acid 
and 20 parts of drug and B contains 70 parts of sodium 
bicarbonate and 30 parts of tartaric acid. 60 parts by 
weight of granules of stage A and 30 parts by weight of 
granules of stage B are mixed along with a lubricant and 
filled into capsule. In dissolution media, the capsule 
shell dissolves and liberates the granules, which showed 
a floating time of more than 8 h and sustained drug 
release of 80% in about 6.5 h. Floating minicapsules of 
pepstatin having a diameter of 0.1-0.2 mm has been 
reported. These minicapsules contain a central core and 
a coating. The central core consists of a granules 
composed of sodium bicarbonate, lactose and a binder, 
which is coated with HPMC polymer. Pepstatin is coated 
on the top of the HPMC layer. The system floats because 
of the release of CO2 in gastric fluid and the pepstatin 
resides in the stomach for prolonged period. Alginates 
have received much attention in the development of 
multiple unit systems
 23
. 
c) Hollow Microspheres:  
These are considered as one of the most promising 
buoyant systems, as they possess the unique advantages 
of multiple unit systems as well as better floating 
properties, because of the central hollow space inside the 
microsphere. The general techniques involved in their 
preparation include simple solvent evaporation method 
and solvent diffusion and evaporation method (Fig: 2). 
The drug release and better floating properties mainly 
depends upon the type of polymer, plasticizer and the 
solvents employed for the formulation. Polymers such as 
Polycarbonate, Eudragit®, and Cellulose acetate were 
used in the preparation of hollow microspheres, and the 
drug release can be modulated by optimizing the 
polymer-plasticizer ratio and the polymer quantity. 
Sustained release floating microspheres using 
polycarbonate were developed, using solvent 
evaporation technique. Aspirin, Griseofulvin and p-
nitroaniline were used as model drugs
 24
. 
 
             Figure 2: Preparation of Hollow Microspheres 
d) Raft Forming Systems:  
Raft forming systems have received much attention for 
the delivery of antacids and drug delivery for GI 
infections and disorders. The basic mechanism involved 
in the raft formation includes the formation of viscous 
cohesive gel in contact with the gastric fluids, wherein 
each portion of the liquid swells forming a continuous 
layer called a raft (Fig: 3). The raft floats because of the 
buoyancy created by the formation of CO2 and act as a 
barrier to prevent the reflux of gastric contents like HCl 
and enzymes into the oesophagus. Usually, the system 
contains a gel forming agent and alkaline bicarbonates 
or carbonates responsible for the formation to make the 
system less dense and float on the gastric fluids
 25
. 
 
Figure 3: Raft forming system 
1.4 MECHANISM OF FLOATING DRUG 
DELIVERY SYSTEM 
Floating drug delivery systems (FDDS) have a bulk 
density less than gastric fluids and so remain buoyant in 
the stomach without affecting the gastric emptying rate 
for a prolonged period of time. While the system is 
floating on the gastric contents (Fig: 4) the drug is 
released slowly at the desired rate from the system. 
After release of drug, the residual system is emptied 
from the stomach. This results in an increased GRT and 
a better control of the fluctuations in plasma drug 
concentration. 
However, besides a minimal gastric content needed to 
allow the proper achievement of the buoyancy retention 
principle, a minimal level of floating force (F) is also 
required to keep the dosage form reliably buoyant on the 
surface of the meal. To measure the floating force 
kinetics, a novel apparatus for determination of resultant 
weight has been reported in the literature. The apparatus 
operates by measuring continuously the force equivalent 
to F (as a function of time) that is required to maintain 
the submerged object. 
The object floats better if F is on the higher positive 
side. This apparatus helps in optimizing FDDS with 
respect to stability and durability of floating forces 
produced in order to prevent the drawbacks of 
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unforeseeable intra-gastric buoyancy capability 
variations 
25
. 
F = F buoyancy - F gravity = (Df - Ds) gV 
Where, F= total vertical force, Df = fluid density, Ds = 
object density, V = volume and g = acceleration due to 
gravity.
 
 
Figure 4: Mechanism of Floating Drug Delivery System 
 
1.5 POLYMERS USED IN FLOATING DRUG 
DELIVERY SYSTEM 
Polymers are used in floating system so as to target the 
drug delivery at specific region in the GI tract i.e. 
stomach. Both synthetic and natural polymers are used 
in the floating drug delivery. Natural polymers used in 
floating system are Guar gum, Chitosan, xanthan gum, 
Gellan gum, Sodium alginate, etc. Synthetic polymers 
used for the floating drug delivery are HPMC, Eudragit, 
ethyl cellulose, etc. 
26
. 
1.5.1 Natural Polymers  
Natural gums (obtained from plants) are hydrophilic 
carbohydrate polymer of high molecular weight. They 
are generally insoluble in organic solvents, like 
hydrocarbon, ether. Gums either water soluble or absorb 
water and swell up or disperse in cold water to give a 
viscous solution or jelly. 
  
Table 2: List of natural polymer 
S.no Polymer Source 
1 Guar gum Endosperm of seed of cynopsis tetragonolobus 
2 Chitosan Shell of marine invertibrates 
3 Xanthum gum Fermentation of glucose by Xanthomonas compestris 
4 Gellan gum Pseudomonas elodea 
5 Sodium alginate Laminaria hyperboria 
 
Natural polymer has advantages over synthetic polymer. 
They are as follows:  
 Biodegradable 
 Biocompatible and non-toxic. 
 Low cost. 
 Environment friendly 
 Local availability.  
Natural polymer has some disadvantages. They are as 
follows:  
 Microbial contamination 
 Batch to batch variation 
 Uncontrolled rate of hydration 
 Reduced viscosity on storage 27 
 
 
1. Guar gum  
Guar gum is naturally occurring galactomannan 
polysaccharide. Guar gum hydrates and swellsin cold 
water forming viscous colloidal dispersions or sols. This 
gelling property retard the drug release and make it a 
flexible carrier for extended release Dosage forms 
26
. In 
pharmaceutical guar gum is used as disintegrant and as a 
polymer in floating drug delivery system.  
Properties of guar gum: 
 It is soluble in water but insoluble in organic 
solvents. 
 Strong hydrogen bond property. 
 Excellent thickening, emulsion, film forming 
property. 
 Ability to control rheology.  
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Advantages of guar gum in floating drug delivery 
system: 
It has been reported that polymer swelling play an 
important role in the pattern and amount of drug release. 
It was found that guar gum formulations were relatively 
insensitive to stirring speed during in vitro drug 
dissolution testing and dissolution profile was not 
affected significantly
28
. 
2. Chitosan  
Chitosan is natural polymer obtainer by deacetylation of 
chitin. It has favorable biological properties such as 
nontoxic, biodegrable, biocompatible. It is a bioadhesive 
polymer and has anti-bacterial properties thus make it 
suitable for site specific delivery. Chitosan is high 
molecular weight polycationic weak base with pka value 
of 6.2-7. On addition to acidic pH of 1.2 or neutral 
media it become buoyant in nature and provide control 
release 
26
. By increasing thickness of chitosan film 
release rate can be decreased 
28
.  
Advantages of chitosan: 
 It forms film that reduces effect of gastrointestinal 
transit time. 
 Hallow microcapsule tend to float on gastric fluid 
for about 12hrs. 
 Release rate of drug followed zero order kinetics 28.  
3. Xanthan gum 
Xanthan gum is a high molecular weight extracellular 
polysaccharide produced by pure culture aerobic 
fermentation of carbohydrate. Xanthan is a long chained 
polysaccharide with large number of trisaccharide side 
chains. Gum also has an excellent solubility and stability 
under acidic and alkaline conditions and in the presence 
of salts and resists common enzymes.  
Advantages of Xanthan gum: 
 It is used to increase or decrease rate of release of 
drug from formulation 
 Soluble in water 
 High viscosity at low concentration 
 It has potential advantage of drug release at zero 
order kinetics.  
Some tablet containing xanthan gum and citric acid 
show buoyancy for more than 24hrs. 
4. Gellan gum  
Gellan gum is an anionic, high molecular weight, 
deacetylated extracellular, linear polysaccharide. This 
gum has an outstanding flavor release, high gel strength, 
an excellent stability, process flexibility, high clarity, 
good film former and thermally reversible gel 
characteristics 
26
. Gellan gum is produced as a 
fermentation product from spingomonas elodea. 
Advantages of Gellan gum: 
 It has excellent flavor release, high gel strength, and 
excellent stability. 
 It forms gel when positively charged ions are added 
 It is used in food product as thickening agent or 
stabilizing agent 
[28]
.  
5. Sodium alginate  
Sodium alginate consists chiefly of the sodium salt of 
alginic acid, which is a mixture of polyuronic acids 
composed of residues of d’mannuronic acid and L 
guluronic acid. The block structure and molecular 
weight of sodium alginate Samples have been 
investigated. 
 Typical Properties: Acidity/alkalinity ph-7.2 (1% 
w/v aqueous solution).  
 Solubility: Practically insoluble in ethanol (95%), 
ether, chloroform, and ethanol/water mixtures in 
which the ethanol content is greater than 30%. Also, 
practically insoluble in other organic Solvents and 
aqueous acidic solutions in which the ph is less than 
3. Slowly soluble in water, forming a viscous 
colloidal Solution.  
 Viscosity (dynamic): Various grades of sodium 
alginate are commercially available that yield 
aqueous solutions of varying Viscosity. Typically, a 
1% w/v aqueous solution, at 208C, will have a 
viscosity of 20–400mpa s (20–400cp). Viscosity 
may vary depending upon concentration, pH, 
temperature, or the Presence of metal ions. Above 
pH 10, viscosity decreases 
29
.  
1.5.2 Synthetic Polymers  
Synthetic polymers are becoming increasingly important 
in pharmaceuticals. Uses of synthetic polymer are as 
binder, film coating agent, etc. Polymer are 
macromolecule having very large, contain a variety of 
functional group. Synthetic polymers are either purely 
synthetic or they are modified form of natural polymer 
know as semi-synthetic. List of synthetic polymer used 
is as follows:  
1. Hydroxypropyl methyl cellulose 
2. Eudragit 
3. Ethyl cellulose 
Disadvantages of synthetic polymer are as follows 
 High cost toxicity environmental pollution 
 Acute and chronic adverse effect 
 Poor biocompatible 
 Inflammatory response and local reaction 27.  
1. Hydroxypropyl methyl cellulose  
Hydroxypropyl methylcellulose ethers belong to an 
extensive family of white to off-white, odorless, water 
soluble polymers that bind, retain water, thicken, form 
films, lubricate. It is a semi synthetic, inert, viscoelastic 
polymer, used as an excipient and controlled-delivery 
component in oral medicaments, found in a variety of 
commercial products.  
Synonyms: Hypromellose, Methocel, Metolose, 
Pharmacoat, Benecel MHPC, E464 etc. 
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Functional category:  
Bioadhesive material, coating agent, controlled-release 
agent, dispersing agent, dissolution enhancer, 
emulsifying agent, emulsion stabilizer, extended-release 
agent, film-forming agent, foaming agent, granulation 
aid, modified-release agent, mucoadhesive, release-
modifying agent, solubilizing agent, stabilizing agent, 
suspending agent, sustained release agent, tablet binder, 
thickening agent, viscosity-increasing agent
30
. 
General properties common to the Hypremellose are 
listed below. Individual type exhibits these properties to 
varying degrees and may have additional properties that 
are desirable for specific applications.  
 Apparent density: 0.25~0.70g/cm3 
 The refractive index=1.336 
 Surface tension: 42 to 56mn/m 
Solubility: Soluble in cold water, forming a viscous 
colloidal solution; practically insoluble in hot water, 
chloroform, ethanol (95%), and ether, but soluble in 
mixtures of ethanol and dichloromethane, mixtures of 
methanol and dichloromethane, and mixtures of water 
and alcohol. Certain grades of HPMC are soluble in 
aqueous acetone solutions, mixtures of dichloromethane 
and propan-2-ol, and other organic solvents. Some 
grades are swellable in ethanol 
31
. 
Applications: 
 In oral products, HPMC is primarily used as a tablet 
binder, in film-coating, and as a matrix for use in 
extended release tablet formulations. Concentrations 
between 2% and 5% w/w may be used as a binder in 
either wet- or dry-granulation processes. High 
viscosity grades may be used to retard the release of 
drugs from a matrix at levels of 10–80% w/w in 
tablets and capsules 
30
. 
 Hypromellose is also used in liquid oral dosage 
forms as a suspending and/or thickening agent at 
concentrations ranging from 0.25–5.0%. 
 Depending upon the viscosity grade, concentrations 
of 2–20% w/w are used for film-forming solutions 
to film-coat tablets. Lower viscosity grades are used 
in aqueous film-coating solutions, while higher-
viscosity grades are used with organic solvents. 
Examples of film coating materials that are 
commercially available include Any Coat C, 
Spectracel, Pharmacoat, and the Methocel E 
Premium LV series. 
 Hypromellose is also used as a suspending and 
thickening agent in topical formulations. 
 Hypromellose at concentrations between 0.45–1.0% 
w/w may be added as a thickening agent to vehicles 
for eye drops and artificial tear solutions. It is also 
used commercially in liquid nasal formulations at a 
concentration of 0.1%. 
 Hypromellose is used as an emulsifier, suspending 
agent, and stabilizing agent in topical gels and 
ointments. 
 
Advantages 
 Water soluble and most abundant polymer in nature 
 Used as a thickener, film former and water retension 
agent 
 Hydrophilic matrix is the simplest sustained release 
technology for oral dosage form 
[32]
. 
2. Eudragit 
Nonproprietary names: BP: Acidum methacrylicum et 
methylis methacrylas polymerisatum 1:2 USPNF: 
Methacrylic acid copolymer 
Synonyms: Polymeric methacrylates. 
Functional category: Film former; tablet binder; tablet 
diluent 
Description:  
Polymethacrylates are synthetic cationic and anionic 
polymers of dimethylaminoethyl methacrylates, 
methacrylic acid, and methacrylic acid esters in varying 
ratios. Several different types are commercially available 
and may be obtained as the dry powder, as an aqueous 
dispersion, or as an organic solution. A (60: 40) mixture 
of acetone and propan-2-ol is most commonly used as 
the organic solvent. Eudragit S 100 is available as 
powder and solvents used for this is 95 % Acetone and 
alcohols which is soluble in intestinal fluid from pH 7 
and used as an enteric coating material. 
Eudragit L and S also referred to as methacrylic acid 
copolymers in the USPNF 23 monograph, are anionic 
copolymerization products of methacrylic acid and 
methyl methacrylate. The ratio of free carboxyl groups 
to the ester is approximately 1:1 in Eudragit L (Type A) 
and approximately 1: 2 in Eudragit S (Type B). Both 
polymers are readily soluble in neutral to weakly 
alkaline conditions ( pH 6– 7) and form salts with 
alkalis, thus affording film coats that are resistant to 
gastric media but soluble in intestinal fluid. Eudragit L-
100 and Eudragit S-100 are white free-flowing powders 
with at least 95 % of dry polymers. 
Incompatibilities: 
Incompatibilities occur with certain polymethacrylate 
dispersions depending upon the ionic and physical 
properties of the polymer and solvent. For example, 
coagulation may be caused by soluble electrolytes, pH 
changes, some organic solvents, and extremes of 
temperature; Interactions between polymethacrylates 
and some drugs can occur, although solid 
polymethacrylates and organic solutions are generally 
more compatible than aqueous dispersions.  
Applications: 
Polymethacrylates (Eudragit) are primarily used in oral 
capsule and tablet formulations as film-coating agents. 
Depending on the type of polymer used, films of 
different solubility characteristics can be produced. 
Eudragit S 100 is soluble in acetone and alcohols and 1N 
NaOH. In contrast, Eudragit L, S and FS types are used 
as enteric coating agents because they are resistant to 
gastric fluid. Different types of enteric coatings are 
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soluble at different pH values: e.g. Eudragit L is soluble 
at pH >6 whereas, Eudragit S and FS are soluble at pH 
>7. The S grade is generally used for coating tablets, 
while the flexible FS 30 D dispersion is preferred for 
coating particles.  
Eudragit RL, RS, NE 30D, NE 40D and NM30D are 
used to form water-insoluble film coats for sustained 
release products. Eudragit RL films are more permeable 
than those of Eudragit RS, and films of varying 
permeability can be obtained by mixing the two types 
together. Polymethacrylates are also used as binders in 
both aqueous and organic wet-granulation processes. 
Larger quantities (5–20%) of dry polymer are used to 
control the release of an active substance from a tablet 
matrix. Solid polymers may be used in direct 
compression processes in quantities of 10–50%. 
Polymethacrylates polymers may additionally be used to 
form the matrix layers of transdermal delivery systems 
and have also been used to prepare novel gel 
formulations for rectal administration 
29
.  
3. Ethyl cellulose  
Ethocel (Ethylcellulose polymers) has been widely used 
in the pharmaceutical industry for over 50 years. 
Ethylcellulose has been used for choice in 
pharmaceutical formulations for various purposes, such 
as taste-masking of bitter actives, moisture protection, 
stabilizer, extended release multiparticulate coating, 
micro-encapsulation of actives, extended release binder 
in inert matrix systems, solvent and extrusion 
granulation.  
Solubility: Ethylcellulose is a water insoluble cellulose 
ether, which is prepared from cellulose, it is a partly O-
ethylated cellulose, its ethoxy content (- OC2H5) is 
between 44-51 %. . It is insoluble at any pH that occurs 
in organism, but in the presence of the gastric Juice it 
undergoes swelling. It is then permeable for water and 
permits extended modified drug release. This makes it 
suitable for improved patient compliance. 
Applications: 
The application of EC in wet extrusion processes is 
limited, since the polymer has considerable elastic 
properties, but can be successfully used as matrix former 
in combination with some plasticizing agents. The 
potential of coarse Ethylcellulose (CPEC) and fine 
particle Ethylcellulose (FPEC) as diluent with high 
molecular weight polyethylene oxide (PEO), which was 
used as an extrusion aid and a binder have shown that 
water is sufficient to prepare a wet granulation product 
when using FPEC. MCC was included in formulations 
to contribute its plasticity to the wetted mass during 
extrusion and to the extrudate during spheronization.  
Ethylcellulose is an ideal polymer for the formation of 
products allowing modified drug release. A small 
number of Ethylcellulose polymers have been approved 
for general pharmaceutical application and are used in 
extended release solid dosage formulations. Several 
types of such Ethylcellulose exist, e.g. Ethocel 4, 
Ethocel 10 and Ethocel 45, which differ in the length of 
the polymer chains, the rate of dissolution, and the 
viscosity of their solution. Ethylcellulose is suitable to 
prepare MR coatings 
33
.  
1.6 LIMITATIONS/DISADVANTAGES OF 
FDDS: 
1. These systems require a high level of fluid in the 
stomach for drug delivery to float and work 
efficiently-coat. 
2. Not suitable for drugs that have solubility or 
stability problem in GIT. 
3. Drugs such as Nifedipine which is well absorbed 
along the entire GIT and which undergoes first pass 
metabolism, may not be desirable 
4. Drugs which are irritant to gastric mucosa are also 
not desirable or suitable. 
5. The drug substances that are unstable in the acidic 
environment of the stomach are not suitable 
candidates to be incorporated in the systems. 
6. The dosage form should be administered with a full 
glass of water (200-250 ml). 
7. These systems do not offer significant advantages 
over the conventional dosage forms for drugs, 
which are absorbed throughout the gastrointestinal 
tract 
34, 35, 36
. 
CONCLUSION 
The FDDS become an additional advantage for drugs 
that are absorbed primarily in the upper segments of GI 
tract, i.e., the stomach, duodenum and jejunum. 
Polymers are used for the purpose of the controlled 
release of drug from dosage form. Polymers are the 
substances which are being used in the formulations for 
many reasons like gelling agents, emulsifying agents, 
viscosity increasing agents, rate retarding agents etc. 
Therefore knowledge of the polymer in field of the drug 
delivery plays an important role. However a lot of work 
is still needed to be done to overcome the different 
physiological and pharmaceutical barriers to develop the 
more effective dosage forms. It is suggested that future 
research work in the FDDSs should be aimed at 
discovering means to accurately control the drug input 
rate into the GI tract for the optimization of the 
pharmacokinetic and toxicological profiles of medicinal 
agents. 
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